Advertisement

Medical Oncology

, 33:74 | Cite as

Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients

  • Firoz Ahmad
  • Anuya Badwe
  • Geeta Verma
  • Simi Bhatia
  • Bibhu Ranjan DasEmail author
Original Paper

Abstract

Somatic mutations in the PIK3CA gene are common in breast cancer and represent a clinically useful marker for prognosis and therapeutic target. Activating mutations in the PI3K p110 catalytic subunit (PIK3CA) have been identified in 18–40 % of breast carcinomas. In this study, we evaluated PIK3CA mutation in 185 Indian breast cancer patients by direct DNA sequencing. PIK3CA mutations were observed in 23.2 % (43/185) of breast tumor samples. PIK3CA mutations were more frequent exon 30 (76.8 %) than in exon 9 (23.2 %). Mutations were mostly clustered within two hotspot region between nucleotides 1624 and 1636 or between 3129 and 3140. Sequencing analysis revealed four different missense mutations at codon 542 and 545 (E542K, E545K, E545A and E545G) in the helical domain and two different amino acid substitutions at codon 1047 (H1047R and H1047L) in the kinase domain. None of the cases harbored concomitant mutations at multiple codons. PIK3CA mutations were more frequent in older patients, smaller size tumors, ductal carcinomas, grade II tumors, lymph node-positive tumors and non-DCIS tumors; however, none of the differences were significant. In addition, PIK3CA mutations were common in ER+, PR+ and HER2+ cases (30 %), and a comparatively low frequency were noted in triple-negative tumors (13.6 %). In conclusion, to our knowledge, this is the largest study to evaluate the PIK3CA mutation in Indian breast cancer patients. The frequency and distribution pattern of PIK3CA mutations is similar to global reports. Furthermore, identification of molecular markers has unique strengths and can provide insights into the pathogenic process of breast carcinomas.

Keywords

Breast cancer India PIK3CA mutation Sequencing analysis 

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have any conflict of interest.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide: IARC cancer base no. 10. 2008. http://globocan.iarc.fr. Accessed 14 Feb 2016.
  2. 2.
    Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Osaki M, Oshimura M, Ito H. PI3K–AKT pathway: its functions and alterations in human cancer. Apoptosis. 2004;9:667–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Sui JQ, Xie KP, Zou W, et al. Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer Prev. 2014;15:6247–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Li SY, Rong M, Grieu F, et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96:91–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Sudhakar N, George Priya Doss C, Thirumal Kumar D, et al. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach. J Biomol Struct Dyn. 2015;34:29–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15:5049–59.CrossRefPubMedGoogle Scholar
  8. 8.
    Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17:667–77.CrossRefPubMedGoogle Scholar
  9. 9.
    Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65:992–1000.CrossRefGoogle Scholar
  10. 10.
    Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486–96.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jensen JD, Knoop A, Laenkholm AV, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol. 2012;23:2034–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ER alpha, PR and ERBB2-based subgroups. Breast Cancer Res. 2012;14:R28.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Maruyama N, Miyoshi Y, Taguchi T, et al. Clinicopathological analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13:408–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Barbareschi M, Buttitta F, Felicioni L, et al. Different prog-nostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007;13:3577–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Ellis MJ, Lin L, Crowder R, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010;119:379–90.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Baselga J, Cortés J, Im S-A, et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Thirty-fifth annual CTRC-AACR San Antonio breast cancer symposium, Dec 4–8, 2012, San Antonio, TX Cancer Res, 2012; 72 (24 Supplement): S5–S1.Google Scholar
  20. 20.
    Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee JY, Park K, Lim SH, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. 2015;6:43731–42.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci. 2015;106:1582–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kandula M, Chennaboina KK, Ys AR, et al. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients. Asian Pac J Cancer Prev. 2013;14:5067–72.CrossRefPubMedGoogle Scholar
  24. 24.
    Thakur NA, Humne AY, Godale LB. Delay in presentation to the hospital and factors affecting it in breast cancer patients attending tertiary care center in Central India. Indian J Cancer. 2015;52:102–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohisto-chemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRefPubMedGoogle Scholar
  27. 27.
    Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3:772–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Barbi S, Cataldo I, De Manzoni G, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res. 2010;29:32.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mao C, Zhou J, Yang Z, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS ONE. 2012;7:e36653.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–73.CrossRefPubMedGoogle Scholar
  31. 31.
    Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Harlé A, Lion M, Lozano N, et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncol Rep. 2013;29:1043–52.PubMedGoogle Scholar
  33. 33.
    Dirican E, Kaya Z, Gullu G, et al. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. Asian Pac J Cancer Prev. 2014;15:9327–33.CrossRefPubMedGoogle Scholar
  34. 34.
    Castaneda CA, Lopez-Ilasaca M, Pinto JA, et al. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastaticbreast cancers. Hematol Oncol Stem Cell Ther. 2014;7:142–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014;32:3212–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Arsenic R, Treue D, Lehmann A, et al. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol. 2015;15:20.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat. 2015;154:155–62.CrossRefPubMedGoogle Scholar
  38. 38.
    Lips EH, Michaut M, Hoogstraat M, et al. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res. 2015;17:134.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Papaxoinis G, Kotoula V, Alexopoulou Z, et al. Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: a hellenic cooperative oncology group (HeCOG) study. PLoS ONE. 2015;10:e0140293.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477–80.CrossRefPubMedGoogle Scholar
  41. 41.
    Karakas B, Colak D, Kaya N, et al. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients’. Cancer Biol Ther. 2013;14:888–96.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Wang YL, Dai X, Li YD, et al. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai. Genet Mol Res. 2015;14:14840–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Deng L, Chen J, Zhong XR, et al. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. PLoS ONE. 2015;10:e0120511.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–81.CrossRefPubMedGoogle Scholar
  45. 45.
    Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534–41.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Liedtke C, Cardone L, Tordai A, et al. PIK3CA activating mutations and chemotherapy sensitivity in stage II–III breast cancer. Breast Cancer Res. 2008;10:R27.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Lai YL, Mau BL, Cheng WH, et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15:1064–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Dunlap J, Le C, Shukla A, et al. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat. 2010;120:409–18.CrossRefPubMedGoogle Scholar
  49. 49.
    Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in situ and invasive breast carcinomas. Cancer Res. 2010;70:5674–8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–91.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci. 2010;107:10208–13.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Dumont AG, Dumont SN, Trent JC. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer. 2012;31:327–34.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Firoz Ahmad
    • 1
  • Anuya Badwe
    • 1
  • Geeta Verma
    • 2
  • Simi Bhatia
    • 2
  • Bibhu Ranjan Das
    • 1
    Email author
  1. 1.Research and DevelopmentSRL LimitedMumbaiIndia
  2. 2.Histopathology DivisionSRL LimitedMumbaiIndia

Personalised recommendations